JP2008538583A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008538583A5 JP2008538583A5 JP2008507988A JP2008507988A JP2008538583A5 JP 2008538583 A5 JP2008538583 A5 JP 2008538583A5 JP 2008507988 A JP2008507988 A JP 2008507988A JP 2008507988 A JP2008507988 A JP 2008507988A JP 2008538583 A5 JP2008538583 A5 JP 2008538583A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- subject
- hydrogen
- apathy
- nefiracetam
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 claims 15
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- -1 2-oxopyrrolidin compound Chemical class 0.000 claims 5
- 206010002942 Apathy Diseases 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 150000002431 hydrogen Chemical group 0.000 claims 4
- NGHTXZCKLWZPGK-UHFFFAOYSA-N nefiracetam Chemical compound CC1=CC=CC(C)=C1NC(=O)CN1C(=O)CCC1 NGHTXZCKLWZPGK-UHFFFAOYSA-N 0.000 claims 4
- 229950004663 nefiracetam Drugs 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 2
- 238000011156 evaluation Methods 0.000 claims 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N gamma-butyrolactam Natural products O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims 2
- 229910052736 halogen Chemical group 0.000 claims 2
- 150000002367 halogens Chemical group 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 238000012360 testing method Methods 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- GMZVRMREEHBGGF-UHFFFAOYSA-N Piracetam Chemical compound NC(=O)CN1CCCC1=O GMZVRMREEHBGGF-UHFFFAOYSA-N 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000005097 aminocarbonylalkyl group Chemical group 0.000 claims 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims 1
- 229960000793 aniracetam Drugs 0.000 claims 1
- ZXNRTKGTQJPIJK-UHFFFAOYSA-N aniracetam Chemical compound C1=CC(OC)=CC=C1C(=O)N1C(=O)CCC1 ZXNRTKGTQJPIJK-UHFFFAOYSA-N 0.000 claims 1
- 230000003542 behavioural effect Effects 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 208000020403 chronic hepatitis C virus infection Diseases 0.000 claims 1
- 230000003920 cognitive function Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000000994 depressogenic effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- HPHUVLMMVZITSG-ZCFIWIBFSA-N levetiracetam Chemical compound CC[C@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-ZCFIWIBFSA-N 0.000 claims 1
- 229960004002 levetiracetam Drugs 0.000 claims 1
- LCAFGJGYCUMTGS-UHFFFAOYSA-N nebracetam Chemical compound O=C1CC(CN)CN1CC1=CC=CC=C1 LCAFGJGYCUMTGS-UHFFFAOYSA-N 0.000 claims 1
- 229950010963 nebracetam Drugs 0.000 claims 1
- 229960001227 oxiracetam Drugs 0.000 claims 1
- IHLAQQPQKRMGSS-UHFFFAOYSA-N oxiracetam Chemical compound NC(=O)CN1CC(O)CC1=O IHLAQQPQKRMGSS-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229960004526 piracetam Drugs 0.000 claims 1
- 229960003389 pramiracetam Drugs 0.000 claims 1
- ZULJGOSFKWFVRX-UHFFFAOYSA-N pramiracetam Chemical compound CC(C)N(C(C)C)CCNC(=O)CN1CCCC1=O ZULJGOSFKWFVRX-UHFFFAOYSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67355505P | 2005-04-20 | 2005-04-20 | |
| US11/406,158 US20060241144A1 (en) | 2005-04-20 | 2006-04-17 | Method for treating apathy syndrome |
| PCT/US2006/015513 WO2006113937A2 (en) | 2005-04-20 | 2006-04-19 | Method for treating apathy syndrome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008538583A JP2008538583A (ja) | 2008-10-30 |
| JP2008538583A5 true JP2008538583A5 (enExample) | 2009-06-04 |
Family
ID=37115988
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008507988A Withdrawn JP2008538583A (ja) | 2005-04-20 | 2006-04-19 | アパシー症候群を治療するための方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US20060241144A1 (enExample) |
| EP (1) | EP1874300B1 (enExample) |
| JP (1) | JP2008538583A (enExample) |
| WO (1) | WO2006113937A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8329741B2 (en) | 2007-06-22 | 2012-12-11 | The Research Foundation Of State University Of New York | Substituted pyrrolidine compounds with central nervous system activity |
| US8962676B2 (en) | 2009-10-22 | 2015-02-24 | University College Dublin, National University Of Ireland, Dublin | Causal therapy of diseases or conditions associated with CNS or PNS demyelination |
| EP2672822A4 (en) * | 2011-02-09 | 2014-08-27 | Univ Johns Hopkins | METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTIONS |
| DE202012012956U1 (de) | 2011-10-21 | 2014-10-16 | Abbvie Inc. | Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen für die Verwendung zur Behandlung von HCV, umfassend Ribavirin aber nicht Interferon |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| SG2014011670A (en) | 2011-10-21 | 2014-10-30 | Abbvie Inc | Combination treatment (eg. with abt-072 or abt -333) of daas for use in treating hcv |
| WO2014078568A1 (en) | 2012-11-14 | 2014-05-22 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| CN103044307A (zh) * | 2013-01-24 | 2013-04-17 | 吉林三善恩科技开发有限公司 | 以2,4-二羟基苯甲酸为前驱体的吡拉西坦药物共晶及其制备方法 |
| EP2968237A4 (en) | 2013-03-15 | 2016-08-31 | Univ Johns Hopkins | METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION |
| CN105142623A (zh) | 2013-03-15 | 2015-12-09 | 艾吉因生物股份有限公司 | 用于改善认知功能的方法和组合物 |
| CN107810002B (zh) | 2015-05-22 | 2021-01-05 | 艾吉因生物股份有限公司 | 左乙拉西坦的延时释放药物组合物 |
| CN106511307B (zh) * | 2015-09-11 | 2018-10-23 | 重庆润泽医药有限公司 | 一种（s）-4-羟基-2氧代-1-吡咯烷乙酰胺缓释胶囊及其制备方法 |
| CN106619530A (zh) * | 2015-10-27 | 2017-05-10 | 重庆润泽医药有限公司 | 一种左旋奥拉西坦颗粒及其制备方法 |
| CN106890154B (zh) * | 2015-12-17 | 2018-10-23 | 重庆润泽医药有限公司 | 一种左旋奥拉西坦泡腾片及其制备方法 |
| US11192914B2 (en) | 2016-04-28 | 2021-12-07 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK279285B6 (sk) * | 1991-05-02 | 1998-09-09 | Daiichi Pharmaceutical Co. | Použitie n-(2,6-dimetylfenyl)-2-(2-oxo-1-pyrolidin |
| US5461157A (en) * | 1992-06-19 | 1995-10-24 | Daiichi Pharmaceutical Co., Ltd. | Process for preparing pyrrolidinylacetamide derivatives |
| ATE224873T1 (de) * | 1995-03-23 | 2002-10-15 | Daiichi Seiyaku Co | Wasserfreie kristalle |
| US6217910B1 (en) * | 1995-07-21 | 2001-04-17 | Daiichi Pharmaceutical Co., Ltd. | Granular preparation and producing process thereof |
| US6107330A (en) * | 1995-08-07 | 2000-08-22 | Daiichi Pharmaceutical Co., Ltd. | Inhibitor for narcotic analgesic dependence/resistance acquisition |
| JPH0987178A (ja) | 1995-09-22 | 1997-03-31 | Toyama Chem Co Ltd | 神経成長因子の作用増強剤 |
| AU727482B2 (en) * | 1996-10-01 | 2000-12-14 | Daiichi Pharmaceutical Co., Ltd. | Mitochondrial membrane stabilizer |
| AU8131198A (en) * | 1997-07-15 | 1999-02-10 | Daiichi Pharmaceutical Co., Ltd. | Prophylactic or therapeutic agent for amnesia |
| AR020115A1 (es) * | 1998-08-06 | 2002-04-10 | Daiichi Seiyaku Co | Agente terapeutico o preventivo para epilepsias rebeldes y uso del compuesto para la produccion de los mismos |
| US20040077709A1 (en) * | 1999-05-31 | 2004-04-22 | Daiichi Pharmaceutical Co., Ltd. | Neuronal death inhibitors |
| US6423739B1 (en) * | 2000-02-23 | 2002-07-23 | Daiichi Pharmaceutical Co., Ltd. | Method for aiding cerebral recovery following neurodegeneration |
| US6348489B1 (en) * | 2000-04-11 | 2002-02-19 | Daiichi Pharmaceutical Co., Ltd. | Method of treating traumatic brain injury and other neuronal disorders |
| EP1356812B1 (en) * | 2000-12-28 | 2009-05-13 | Hamilton Pharmaceuticals, Inc. | Medicines for treatment and prevention of neurogenic pain |
| JP2005501108A (ja) * | 2001-08-22 | 2005-01-13 | 第一製薬株式会社 | 神経変性治療におけるネフィラセタムの使用 |
-
2006
- 2006-04-17 US US11/406,158 patent/US20060241144A1/en not_active Abandoned
- 2006-04-19 WO PCT/US2006/015513 patent/WO2006113937A2/en not_active Ceased
- 2006-04-19 JP JP2008507988A patent/JP2008538583A/ja not_active Withdrawn
- 2006-04-19 EP EP06758559A patent/EP1874300B1/en not_active Not-in-force
-
2009
- 2009-11-03 US US12/611,704 patent/US20100048634A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008538583A5 (enExample) | ||
| CA3092279C (en) | Treatment of immune-related and inflammatory diseases | |
| CN1084618C (zh) | 5－羟色胺拮抗剂的新应用 | |
| RU2317294C2 (ru) | (имидазол-1-илметил)пиридазин в качестве блокатора nmda рецептора | |
| JP5925065B2 (ja) | 医薬組成物 | |
| JP2008513498A5 (enExample) | ||
| JP2007145875A5 (enExample) | ||
| HUP0204526A2 (hu) | 2-Oxo-1-pirrolidin-származékok, eljárás előállításukra és alkalmazásuk | |
| JP2006517939A5 (enExample) | ||
| SI3075726T1 (en) | DERIVATIVES OF UREA OR ITS PHARMACOLOGICAL RECRUITABLE SALTS USED AS FORMIL PEPTIDAL RECEPTOR LIKE 1 (FPRL-1) AGONISTS | |
| JP2006509749A5 (enExample) | ||
| JP2010534647A5 (enExample) | ||
| JP2006525276A5 (enExample) | ||
| JP2008513496A5 (enExample) | ||
| EA200801165A1 (ru) | Антагонисты неосновного рецептора-1 меланинконцентрирующего гормона | |
| CN1430609A (zh) | 取代的1－氨基烷基内酰胺化合物及其作为毒蕈碱受体拮抗剂的用途 | |
| RU2007120454A (ru) | Производные хинуклидина и их применение в качестве антагонистов мускариновых рецепторов м3 | |
| US20250228838A1 (en) | Methods of use of cyclic amide derivatives to treat sigma receptor mediated disorders | |
| US20100099714A1 (en) | AMPA and NMDA Receptor Antagonists for Neurodegenerative Diseases | |
| MA28111A1 (fr) | Derives des | |
| RU2007119390A (ru) | Соединения 4-метоксиметил-пирролидин-2-карбоновой кислоты и их производные - ингибиторы вируса гепатита с | |
| JP2004523557A5 (enExample) | ||
| RU2311408C2 (ru) | Производные аминотетралина в качестве антагонистов мускаринового рецептора | |
| JP2004529117A5 (enExample) | ||
| JP2008500378A5 (enExample) |